Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1.04B |
| 2 |
Palo Alto Networks
PANW
|
+$957M |
| 3 |
Medtronic
MDT
|
+$433M |
| 4 |
Pinterest
PINS
|
+$422M |
| 5 |
Colgate-Palmolive
CL
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.38B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$967M |
| 3 |
Apple
AAPL
|
+$847M |
| 4 |
Meta Platforms (Facebook)
META
|
+$700M |
| 5 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$576M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.9% |
| 2 | Financials | 7.33% |
| 3 | Healthcare | 6.04% |
| 4 | Consumer Discretionary | 5.46% |
| 5 | Communication Services | 3.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3926
Procept Biorobotics
PRCT
$1.17B
| $42K | ﹤0.01% |
1,285
+110
| +9% | +$4K |
|
3927
Construction Partners
ROAD
$6.77B
| $42K | ﹤0.01% |
2,001
-4,624
| -70% | -$109K |
|
3928
Solid Biosciences
SLDB
$900M
| $42K | ﹤0.01% |
4,544
-645
| -12% | -$6.7K |
|
3929
Transmedics
TMDX
$2.91B
| $42K | ﹤0.01% |
1,350
-2,972
| -69% | -$79.3K |
|
|
RKLY
3930
DELISTED
Rockley Photonics Holdings Limited
RKLY
| $42K | ﹤0.01% |
19,278
+4,734
| +33% | +$14.5K |
|
3931
Compugen
CGEN
$228M
| $41K | ﹤0.01% |
22,198
+20,198
| +1,010% | +$43.6K |
|
3932
Culp Inc
CULP
$44.1M
| $41K | ﹤0.01% |
9,477
-1,015
| -10% | -$6.23K |
|
3933
Delek Logistics
DKL
$3.02B
| $41K | ﹤0.01% |
+837
| New | +$42.3K |
|
3934
Grid Dynamics Holdings
GDYN
$615M
| $41K | ﹤0.01% |
2,439
-5,942
| -71% | -$97.1K |
|
3935
Gossamer Bio
GOSS
$87M
| $41K | ﹤0.01% |
+4,979
| New | +$38.6K |
|
3936
Mustang Bio
MBIO
$4.55M
| $41K | ﹤0.01% |
93
-16
| -15% | -$8.86K |
|
3937
Rocket Lab Corp
RKLB
$51.8B
| $41K | ﹤0.01% |
10,703
-72,115
| -87% | -$424K |
|
3938
Rallybio
RLYB
$85.8M
| $41K | ﹤0.01% |
676
-267
| -28% | -$20.1K |
|
3939
Valaris Ltd Warrants
VAL.WS
$667M
| $41K | ﹤0.01% |
8,116
| – | – |
|
|
RXDX
3940
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $41K | ﹤0.01% |
1,468
-3,524
| -71% | -$102K |
|
3941
Columbus McKinnon
CMCO
$584M
| $40K | ﹤0.01% |
1,407
-3,242
| -70% | -$112K |
|
|
CUK
3942
DELISTED
Carnival PLC
CUK
| $40K | ﹤0.01% |
5,000
| – | – |
|
3943
StealthGas
GASS
$319M
| $40K | ﹤0.01% |
12,500
| – | – |
|
3944
Goldman Sachs BDC
GSBD
$1.1B
| $40K | ﹤0.01% |
+2,407
| New | +$44.4K |
|
3945
ImmunityBio
IBRX
$8.1B
| $40K | ﹤0.01% |
10,863
-778
| -7% | -$3.13K |
|
3946
iShares Russell 3000 ETF
IWV
$20.3B
| $40K | ﹤0.01% |
+185
| New | +$43.8K |
|
3947
KraneShares Electric Vehicles and Future Mobility Index ETF
KARS
$80.2M
| $40K | ﹤0.01% |
1,121
| – | – |
|
3948
Lands' End
LE
$403M
| $40K | ﹤0.01% |
3,742
-2,374
| -39% | -$31.2K |
|
3949
Mirion Technologies
MIR
$3.91B
| $40K | ﹤0.01% |
+6,876
| New | +$50.6K |
|
3950
Phathom Pharmaceuticals
PHAT
$692M
| $40K | ﹤0.01% |
4,767
-2,200
| -32% | -$22.6K |
|
Similar funds
Barclays's Q2 2022 Portfolio in Review
As of Q2 2022, Barclays held 5,544 positions worth $163B, up 28% from $128B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Barclays deployed $63.1B of net new capital in Q2 2022, opening 560 new positions and adding to 1,332 existing holdings. Its largest new stake was Fisker Inc.: 3,607,227 shares worth $30.9M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 22% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.38B trimmed.
- Barclays's largest Q2 2022 buy was Fisker Inc.: 3,607,227 shares worth $30.9M.
- Barclays added most to State Street Consumer Discretionary Select Sector SPDR ETF in Q2 2022, an estimated $1.04B increase.
- Barclays's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.38B.
- Barclays fully exited Cerner Corp in Q2 2022, selling an estimated $432M.
- Barclays's ten largest holdings make up 39% of its $163B portfolio in Q2 2022.
- Barclays opened 560 new positions and closed 413 in Q2 2022.
- Barclays's portfolio value rose 28% quarter-over-quarter to $163B.
Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.